Effect of Tenofovir/Emtricitabine/Efavirenz with and without Chloroquine in Patients with HIV/AIDS C3: Double Blinded Randomized Clinical Trial
|Marco Isaac Banda Lara1*, Martínez-García María del Carmen2, Vázquez-Rosales José Guillermo2, Rendón-Macías Mario Enrique2, Flores-Hernández Sergio3, Rivera-Benítez César1, Santos-González Margarito1 and Carrillo-Avalos Blanca4|
|1Servicio de Infectología, Hospital General de México. Eje 2A Sur (Dr. Balmis) #148, Col. Doctores, Del. Cuauhtémoc, CP 06726. Ciudad de México, D.F., México|
|2Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social. Av. Cuauhtémoc #330, Col Doctores, Del. Cuauhtémoc, C.P. 06720. Ciudad de México, D.F., México|
|3Instituto Nacional de Salud Pública. Universidad No. 655, Col. Santa María Ahuacatitlán, Cerrada los Pinos y Caminera, CP 62100. Cuernavaca, Morelos, México|
|4Facultad de Medicina, Universidad Autónoma de San Luis Potosi, México|
|Corresponding Author :||Marco Isaac Banda Lara
Hospital General de Zona #2
San Luis Potosí. Benigno Arriaga esq Cuauhtémoc
Colonia Moderna, CP 78233, San Luis Potosí, San Luis Potosí, México
Tel: 52 4448120136
E-mail: [email protected]
|Received: October 21, 2015 Accepted: November 10, 2015 Published: November 16, 2015|
|Citation: Lara MIB, Carmen MGMD, Guillermo VRJ, Enrique RMM, Sergio FH, et al. (2015) Effect of Tenofovir/Emtricitabine/Efavirenz with and without Chloroquine in Patients with HIV/AIDS C3: Double Blinded Randomized Clinical Trial. J Pharmacovigil 3:182. doi:10.4172/2329-6887.1000182|
|Copyright: © 2015 Lara MIB, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
|Related article at Pubmed, Scholar Google|
Background: The use of antiretroviral therapy (ART) reduces both mortality and morbidity of patients with HIV/ AIDS. The effects of chloroquine against HIV replication are widely known.
Objective: To demonstrate that beginning HIV treatment with ART (tenofovir/emtricitabine/efavirenz) + chloroquine increases by at least 20% the proportion of patients with viral load (VL) <50 copies/mL and >200 CD4+/mcL compared to patients receiving only ART at six months follow up.
Method: A randomized double-blind clinical trial was performed in 95 patients at the Infectious Diseases Department of the Hospital General de Mexico diagnosed with HIV/AIDS classification C3 before their first ART: 48 patients in the ART + placebo group and 47 in the ART + chloroquine group.
Results: A difference of 37% at six months of treatment in advantage of the group of ART + chloroquine (p<0.001), and seven times greater chance of improvement using chloroquine in the first six months of treatment. Chloroquine decreased the frequency of IRIS in 20%, compared with the group that initiated ART only at six months follow-up with statistical difference (p=0.029).
Conclusion: Chloroquine can improve the immune response and decrease the frequency of inflammatory syndrome by immune reconstitution at six months if added to the initial ART with tenofovir/emtricitabine/efavirenz.